NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, Forecast & News

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by $0.09. View Apellis Pharmaceuticals' Earnings History.

Apellis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Apellis Pharmaceuticals.

10 brokerages have issued 12 month price objectives for Apellis Pharmaceuticals' stock. Their forecasts range from $23.00 to $80.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $46.09 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.

Headlines about APLS stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apellis Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Apellis Pharmaceuticals.

Apellis Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,670,000 shares, an increase of 22.4% from the January 15th total of 5,450,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is currently 4.9 days. Approximately 12.6% of the shares of the company are sold short. View Apellis Pharmaceuticals' Current Options Chain.

Some companies that are related to Apellis Pharmaceuticals include Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA), The Medicines (MDCO) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), KemPharm (KMPH), Aurinia Pharmaceuticals (AUPH), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM), ChemoCentryx (CCXI) and Exelixis (EXEL).

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Apellis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (3.10%), State Street Corp (3.07%), Victory Capital Management Inc. (2.90%), FIL Ltd (1.86%), Barclays PLC (1.55%) and Jennison Associates LLC (1.48%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Lukas Scheibler, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan. View Institutional Ownership Trends for Apellis Pharmaceuticals.

APLS stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Fiduciary Trust Co., Jane Street Group LLC, SG Americas Securities LLC, Candriam Luxembourg S.C.A., Pictet Asset Management Ltd., Baird Financial Group Inc. and Prudential Financial Inc.. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Cedric Francois and Pascal Deschatelets. View Insider Buying and Selling for Apellis Pharmaceuticals.

APLS stock was purchased by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, Victory Capital Management Inc., Farallon Capital Management LLC, Victory Capital Management Inc., FIL Ltd, FMR LLC and Bank of Montreal Can. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Lukas Scheibler, Morningside Venture Investment and Timothy Eugene Sullivan. View Insider Buying and Selling for Apellis Pharmaceuticals.

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APLS stock can currently be purchased for approximately $36.87.

Apellis Pharmaceuticals has a market capitalization of $2.76 billion. The company earns $-127,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.View Additional Information About Apellis Pharmaceuticals.

The official website for Apellis Pharmaceuticals is http://www.apellis.com/.

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]